Compare Novartis AG (NVS) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total World Stock Index Fund ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Total World Stock Index Fund ETF trades at $156.44. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VT | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $159.35 |
52-Week Low | $113.50 | $128.41 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VT trades at $154.29, down 0.32% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The ETF's broad global diversification and low expense ratio of 0.06% are key strengths, though financial ratios are not disclosed in the provided data. Recent news highlights comparisons with competing international ETFs, emphasizing VT's comprehensive market exposure.
The outlook remains cautious due to bearish technical signals and competitive pressures from lower-cost alternatives. Risks include expense ratio disadvantages versus peers and global market volatility. Analyst sentiment is mixed, with ongoing debates about optimal international ETF selection influencing investor positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
